Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why
01:01pm, Monday, 22'nd Dec 2025
Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher
10:56am, Monday, 22'nd Dec 2025
Keros Therapeutics (KROS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
10:26am, Tuesday, 16'th Dec 2025
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements wit
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
10:16am, Monday, 15'th Dec 2025
Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
01:01pm, Friday, 12'th Dec 2025
Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.
KROS vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Friday, 12'th Dec 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc.
03:52am, Friday, 12'th Dec 2025
Federated Hermes Inc. lessened its position in Keros Therapeutics, Inc. (NASDAQ: KROS) by 46.6% during the second quarter, according to the company in its most recent 13F filing with the Securities an
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
10:55am, Friday, 28'th Nov 2025
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
KROS or NVZMY: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 26'th Nov 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Novozymes A/S (NVZMY). But which of these two stocks offers valu
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
10:56am, Wednesday, 26'th Nov 2025
The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
Keros Therapeutics Announces Final Results of Tender Offer
04:01pm, Thursday, 20'th Nov 2025
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tende
Keros Therapeutics Announces Preliminary Results of Tender Offer
06:00am, Wednesday, 19'th Nov 2025
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the �
5 Undervalued Stocks That Are Poised for Growth in November
08:36am, Thursday, 13'th Nov 2025
Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.
KROS vs. ARGX: Which Stock Is the Better Value Option?
12:49pm, Monday, 10'th Nov 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks is more a
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?
10:56am, Monday, 10'th Nov 2025
The consensus price target hints at a 42.8% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
